Plus Therapeutics announced on August 26, 2025, that it received a letter from Nasdaq on August 22, 2025, confirming its compliance with Nasdaq Listing Rule 5550(b). This rule pertains to both the Market Value of Listed Securities (MVLS) standard and the alternative stockholders’ equity threshold.
The company now satisfies both the $35 million MVLS standard and the $2.5 million stockholders’ equity standard. This compliance ensures the company meets key financial requirements for continued listing.
Nasdaq has granted the company the remainder of the previously announced grace period, through November 12, 2025, to regain compliance with the $1.00 bid price rule. The company remains under a one-year panel monitoring period for the Equity Standard until August 22, 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.